Base Pair Biotechnologies

Base Pair Biotechnologies is a Houston-based aptamer discovery and development company, spun out of Biotex, Inc. in 2012.  The company provides custom aptamer discovery and development services, as well as a growing number of catalog aptamers. They’ve complied a significant intellectual property portfolio in the aptamer space, servicing a diverse range of customer segments, including pharma and biopharma, diagnostics, environmental testing, and veterinary medicine.

Aptamers are small, synthetic RNA or DNA molecules that fold into unique shapes, which enable them to selectively and tightly bind to molecular, viral or cellular targets. Base Pair combines a highly customized aptamer discovery approach with a patented multiplexing technology, bringing together DNA barcoding and next-generation sequencing to enable simultaneous identification of aptamers that can bind up to 30 different targets.

“Aptamers provide solutions to customer problems that are hard, if not impossible to solve with antibodies,” said Vicki Singer, President and CEO of Base Pair, “especially for small molecule targets, toxic molecules, and targets with low antigenicity.  Base Pair’s unique value proposition lies in the scientific strength and creativity of its team, which includes cell biologists, molecular and microbiologists and biochemists, with decades of experience.”

“The focus on problem-solving, rather than aptamer generation, really sets Base Pair apart,” said Scott Bryan, Eventi Capital’s Managing Partner.  “We believe the company is poised to rapidly expand in multiple market sectors and are pleased to have the opportunity to participate.”